Anti-cancer combination therapy
The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
14.12.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists. |
---|---|
Bibliography: | Application Number: US201815995375 |